Real-time Estimate
Cboe BZX
02:49:33 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
1.735
USD
|
+1.46%
|
|
-10.57%
|
+23.05%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,223
|
441.2
|
234.1
|
286.3
|
-
|
-
|
Enterprise Value (EV)
1 |
861.6
|
183.2
|
72.97
|
234.9
|
149.5
|
54.68
|
P/E ratio
|
-6.31
x
|
-2.71
x
|
-5.64
x
|
-2.74
x
|
-2.22
x
|
-3.33
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
60
x
|
1,894
x
|
1,094
x
|
1,145
x
|
1,145
x
|
9.27
x
|
EV / Revenue
|
42.3
x
|
786
x
|
341
x
|
940
x
|
598
x
|
1.77
x
|
EV / EBITDA
|
-6.35
x
|
-1.27
x
|
-0.58
x
|
-2.17
x
|
-1.06
x
|
-0.33
x
|
EV / FCF
|
-13.6
x
|
-1.74
x
|
-0.86
x
|
-2.36
x
|
-1.24
x
|
-0.38
x
|
FCF Yield
|
-7.36%
|
-57.4%
|
-116%
|
-42.3%
|
-80.9%
|
-265%
|
Price to Book
|
3.25
x
|
1.69
x
|
0.96
x
|
1.92
x
|
1.35
x
|
1.09
x
|
Nbr of stocks (in thousands)
|
160,298
|
165,875
|
166,010
|
167,413
|
-
|
-
|
Reference price
2 |
7.630
|
2.660
|
1.410
|
1.710
|
1.710
|
1.710
|
Announcement Date
|
3/30/22
|
3/24/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
20.38
|
0.233
|
0.214
|
0.25
|
0.25
|
30.88
|
EBITDA
1 |
-135.8
|
-144.6
|
-125.2
|
-108.4
|
-140.5
|
-164.2
|
EBIT
1 |
-135.8
|
-144.8
|
-125.5
|
-108.3
|
-152.5
|
-140.4
|
Operating Margin
|
-666.49%
|
-62,140.34%
|
-58,631.31%
|
-43,320%
|
-61,016.07%
|
-454.63%
|
Earnings before Tax (EBT)
1 |
-136.6
|
-135.2
|
-39.29
|
-110.3
|
-152.7
|
-130.4
|
Net income
1 |
-167.8
|
-152.4
|
-40.22
|
-110.4
|
-150.2
|
-127.5
|
Net margin
|
-823.56%
|
-65,401.29%
|
-18,796.26%
|
-44,160%
|
-60,085.93%
|
-412.94%
|
EPS
2 |
-1.210
|
-0.9800
|
-0.2500
|
-0.6233
|
-0.7700
|
-0.5140
|
Free Cash Flow
1 |
-63.42
|
-105.2
|
-84.38
|
-99.35
|
-120.9
|
-145.1
|
FCF margin
|
-311.24%
|
-45,167.38%
|
-39,428.5%
|
-39,740%
|
-48,361.07%
|
-469.91%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
3/24/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
0.266
|
0.23
|
-
|
0.17
|
0.024
|
0.038
|
0.037
|
0.172
|
0.087
|
0.018
|
-
|
-
|
-
|
0.3
|
-
|
EBITDA
1 |
-33.37
|
-45.15
|
-33.38
|
-35.34
|
-38.39
|
-37.51
|
-33.15
|
-31.78
|
-26.76
|
-33.46
|
-29.55
|
-27.3
|
-28.45
|
-28.65
|
-
|
EBIT
1 |
-33.36
|
-45.18
|
-33.44
|
-35.36
|
-38.42
|
-37.56
|
-33.21
|
-31.86
|
-26.83
|
-33.56
|
-24.08
|
-26.97
|
-28.27
|
-28.93
|
-33.2
|
Operating Margin
|
-12,541.73%
|
-19,641.3%
|
-
|
-20,798.24%
|
-160,095.83%
|
-98,855.26%
|
-89,767.57%
|
-18,524.42%
|
-30,843.68%
|
-186,450%
|
-
|
-
|
-
|
-9,644.44%
|
-
|
Earnings before Tax (EBT)
1 |
-26.47
|
-48.58
|
-31.92
|
-30.81
|
-33.13
|
-39.32
|
-33.16
|
-31.66
|
43.85
|
-18.32
|
-25.68
|
-26.53
|
-28.8
|
-29.27
|
-32.5
|
Net income
1 |
-31.16
|
-88.88
|
-36.87
|
-36.62
|
-33.89
|
-45.01
|
-33.14
|
-33.04
|
44.24
|
-18.29
|
-26.71
|
-26.27
|
-28.5
|
-28.93
|
-34.2
|
Net margin
|
-11,713.53%
|
-38,642.17%
|
-
|
-21,540%
|
-141,195.83%
|
-118,450%
|
-89,554.05%
|
-19,210.47%
|
50,855.17%
|
-101,622.22%
|
-
|
-
|
-
|
-9,644.44%
|
-
|
EPS
2 |
-0.2100
|
-0.6200
|
-0.2400
|
-0.2400
|
-0.2200
|
-0.2800
|
-0.2100
|
-0.2100
|
0.2500
|
-0.1200
|
-0.1700
|
-0.1567
|
-0.1600
|
-0.1467
|
-0.2000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
3/30/22
|
5/16/22
|
8/15/22
|
11/10/22
|
3/24/23
|
5/11/23
|
8/10/23
|
11/14/23
|
3/28/24
|
5/15/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
362
|
258
|
161
|
51.4
|
137
|
232
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-63.4
|
-105
|
-84.4
|
-99.4
|
-121
|
-145
|
ROE (net income / shareholders' equity)
|
-71.8%
|
-47.8%
|
-16%
|
-53.1%
|
-59.2%
|
-46.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
2.350
|
1.570
|
1.460
|
0.8900
|
1.270
|
1.570
|
Cash Flow per Share
2 |
-0.4600
|
-0.6700
|
-0.5300
|
-0.4600
|
-0.5000
|
-0.4200
|
Capex
1 |
0.17
|
0.77
|
0.26
|
2.65
|
3.21
|
3.92
|
Capex / Sales
|
0.85%
|
331.76%
|
121.03%
|
1,060%
|
1,285.87%
|
12.7%
|
Announcement Date
|
3/30/22
|
3/24/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
1.71
USD Average target price
11.8
USD Spread / Average Target +590.06% Consensus |
1st Jan change
|
Capi.
|
---|
| +23.05% | 286M | | +40.43% | 50.93B | | -0.36% | 42.12B | | +49.62% | 42.05B | | -7.20% | 29.18B | | +12.85% | 26.02B | | -21.70% | 18.9B | | +7.09% | 13.21B | | +24.56% | 12.17B | | +30.01% | 12.16B |
Other Biotechnology & Medical Research
|